Molecular structure of Nafamostat mesylate, CAS Number: 82956-11-4
Nafamostat mesylate (CAS 82956-11-4)
See product citations (4)
Alternate Names:
Nafamstat Mesilate; Futhan; 6-Amidino-2-naphthyl-4-guanidinobenzoate Dimethanesulfonate
Application:
Nafamostat mesylate is a highly effective tryptase inhibitor
CAS Number:
82956-11-4
Purity:
≥98%
Molecular Weight:
539.6
Molecular Formula:
C19H17N5O2•2CH4O3S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Nafamostat mesylate is a highly effective tryptase (Ki=95.3 pM) inhibitor. The compound has the ability to promote synthesis of interferon-gamma, tumor necrosis factor-alpha, IL-12, and IL-18. Additionally, Nafamostat mesylate can induce production of intercellular adhesion molecules-1, B7.1, B7.2, CD40 and CD40 ligand in human blood mononuclear cells. Nafamostat mesylate may act to decrease levels of plasma myeloperoxidase, and has also been used in ERCP pancreatitis studies. Nafamostat mesylate is an inhibitor of Factor X, Factor XII, granzyme A and KLK.
Nafamostat mesylate (CAS 82956-11-4) References
- Nafamostat mesilate is an extremely potent inhibitor of human tryptase. | Mori, S., et al. 2003. J Pharmacol Sci. 92: 420-3. PMID: 12939527
- Nafamostat mesilate induces production of interleukin-12 and -18 in human peripheral blood mononuclear cells. | Katsuno, G., et al. 2005. J Pharmacol Sci. 98: 463-6. PMID: 16093612
- Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis. | Choi, CW., et al. 2009. Gastrointest Endosc. 69: e11-8. PMID: 19327467
- Nafamostat mesylate inhibits chlamydial intracellular growth in cell culture and reduces chlamydial infection in the mouse genital tract. | Peng, L., et al. 2020. Microb Pathog. 147: 104413. PMID: 32712115
- Identification of impurities in nafamostat mesylate using HPLC-IT-TOF/MS: A series of double-charged ions. | Zhang, Y., et al. 2020. J Pharm Anal. 10: 346-350. PMID: 32923008
- The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19. | Li, K., et al. 2021. mBio. 12: e0097021. PMID: 34340553
- Co-Spray Dried Nafamostat Mesylate with Lecithin and Mannitol as Respirable Microparticles for Targeted Pulmonary Delivery: Pharmacokinetics and Lung Distribution in Rats. | Kang, JH., et al. 2021. Pharmaceutics. 13: PMID: 34575594
- Nafamostat mesylate overcomes endocrine resistance of breast cancer through epigenetic regulation of CDK4 and CDK6 expression. | Lin, YT., et al. 2022. Transl Oncol. 15: 101302. PMID: 34890965
- Identification of nafamostat mesylate as a selective stimulator of NK cell IFN-γ production via metabolism-related compound library screening. | Yang, Q., et al. 2022. Immunol Res. 70: 354-364. PMID: 35167033
- Nafamostat mesylate as a broad-spectrum candidate for the treatment of flavivirus infections by targeting envelope proteins. | Yan, Y., et al. 2022. Antiviral Res. 202: 105325. PMID: 35460703
- Delayed administration of nafamostat mesylate inhibits thrombin-mediated blood-spinal cord barrier breakdown during acute spinal cord injury in rats. | Zhao, C., et al. 2022. J Neuroinflammation. 19: 189. PMID: 35842640
- Nafamostat mesylate prevents metastasis and dissemination of neuroblastoma through vascular endothelial growth factor inhibition. | Morimoto, M., et al. 2022. Mol Clin Oncol. 17: 138. PMID: 35949892
- Active inhibitory effect of nafamostat mesylate against the elevation of plasma myeloperoxidase during hemodialysis. | Inose, K., et al. 1997. Nephron. 75: 420-5. PMID: 9127328
Inhibitor of:
A430107O13Rik, Antipain dihydrochloride, ASTL, C1Q (complement C1q), C1r, C1rb, C1rL, C3a, C5L2, C7, C8α, C9, carboxypeptidase B2 (TAFI), cathepsin G, Cfhr2, Corin, CPA2, CPB, cystatin C, cystatin E/M, Desc4, EG433016, EG436523, ENSMUSG00000071517, Factor X, Factor XII, FHR-2, FHR-3, Gastric Lipase, Gm46, Granzyme, granzyme A, granzyme C, granzyme E, granzyme F, granzyme M, granzyme N, HABP2, HAI-1, hippocalcin, HtrA4, Kininogen I, Kininogen II, KLK, KLK (Kallikrein related peptidase), Klk1b4, Klk26, KLKb2, Klkb21, Klkb22, Marapsin 2, Mast Cell Chymase, Mast Cell Protease, Mast Cell Protease 2, Mast Cell Protease 5, Mast Cell Protease 8, Mast Cell Tryptase, Matriptase, Matriptase-2, MC-CPA, Mesotrypsinogen, neuroserpin, Neurotrypsin, PAI-2, PI-9, Polyserase-1, PRB1-3, PRB3, Prostasin, Protease, PRSS16, Prss28, Prss32, Prss34, PRSS35, PRSS37, PRSS44, Prss47, PRSS51, PRSSL1, RIG-I, S2P, SerpinA11, SerpinA1b, SerpinA1c, SerpinA1e, SerpinA1f, SerpinA2, SerpinA3a, SerpinA3b, SerpinA3c, SerpinA3f, SerpinA3j, SerpinA3m, SerpinA3n, SerpinB1c, Serpinb3c, Serpinb3d, SerpinB6B, SerpinB6C, SerpinB8, SERPINE3, Spi11, SPINK14, SPINK2, SPINK6, SR-2C, TATI, Testican-2, TGE Virus, TMPRSS11B, TMPRSS11F, TMPRSS12, TMPRSS13, TMPRSS2, TMPRSS3, TMPRSS4, TMPRSS5, TPSB1, TPSB3, Trypsin X3, Trypsin-1, Trypsin-3, Trypsin-4, Tryptase γ, and uPA.Activator of:
1700074P13Rik, Annexin II, C1INH, C2, C4BPβ, C5β, C9, Chromozym TRY, CPA1, CR1L, Desc4, HSBP1L1, Klk26, Klkb16, Klkb21, KLKb8, plasma kallikrein, PRSS16, Prss28, Prss29, PRSS35, Prss39, Prss47, SerpinA1a, SERPINE3, stefin A1L1, TLCK, TMPRSS11A, TMPRSS11C, TMPRSS11E2, TMPRSS11F, TMPRSS13, TMPRSS3, TMPRSS5, TMPRSS7, TMPRSSs8, TPSB1, and UNQ9391.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Nafamostat mesylate, 10 mg | sc-201307 | 10 mg | $80.00 | |||
Nafamostat mesylate, 50 mg | sc-201307A | 50 mg | $300.00 |